about
Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumorsHER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib.Treatment and Prevention of Bone Metastases from Breast Cancer: A Comprehensive Review of Evidence for Clinical PracticeMalignant Cardiac Tamponade from Non-Small Cell Lung Cancer: Case Series from the Era of Molecular Targeted Therapy.Pathogenic PALB2 mutation in metastatic pancreatic adenocarcinoma and neuroendocrine tumour: A case report.Serum Biomarkers Associated with Clinical Outcomes Fail to Predict Brain Metastases in Patients with Stage IV Non-Small Cell Lung Cancers.A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers.HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers.PET monitoring of liver directed selective internal radionuclide therapy for metastatic gastro-oesophageal cancer.Capturing Genomic Evolution of Lung Cancers through Liquid Biopsy for Circulating Tumor DNA.Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.Systematic Review of the Role of Targeted Therapy in Metastatic Neuroendocrine Tumors.What does the future hold for immunotherapy in cancer?A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel.Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers.Measurement of preoperative lobar lung function with computed tomography ventilation imaging: progress towards rapid stratification of lung cancer lobectomy patients with abnormal lung function.Localized malignant pleural mesothelioma with renal metastasis.Dramatic response to selective internal radiation therapy for unresectable hepatocellular carcinoma.The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials.Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target.Circulating tumor DNA analysis to assess risk of progression after long-term response to PD-(L)1 blockade in NSCLCEntrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumorsHER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung CancersTargeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid TumorsHigh-intensity sequencing reveals the sources of plasma circulating cell-free DNA variantsGenomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized GliomasCirculating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable AlterationsPhase I Study of Intermittent High-Dose Lapatinib Alternating with Capecitabine for HER2-Positive Breast Cancer Patients with Central Nervous System MetastasesEGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer
P50
Q27853154-0ABAD003-663D-429D-8835-0B7227454723Q27853242-D0D32228-D21F-4C3E-B232-66C7960B5682Q35667196-67F46F65-A6A0-4E61-966F-8CAD1FD3EF87Q35750661-8A22232C-7749-4C3A-A06F-135F248F48D0Q35803533-DEEA92BC-CEA3-4225-AF15-664C54BDFD43Q35885064-85439848-F223-4B80-84FE-F385636CFF35Q36384490-54C2D728-5281-4D54-868C-FFD9410FA86AQ36423790-4BA22E08-0A53-4198-9450-B12410FD7AEAQ37063745-EEDD571A-75AC-4D64-A5CB-3AE375974BB8Q37723666-B4A2ACE9-1718-4A30-B160-193575E4A15FQ38586991-73BBA415-0616-485C-B637-604A6DE0169DQ38809059-6FDCA3FB-082E-4DE6-BBDB-D62EA3B83246Q38856436-64B82A14-9FFB-49F3-82D8-C8BA7AFA78A4Q40298545-92D8D3E3-2696-4A3A-8FE6-B26F27FF95A8Q40605757-8A6A7B77-68A2-4317-A9B9-254E0903BA73Q40653282-30212B47-AD81-47DC-B386-700C416C0CDCQ41729527-0CED8BB9-1AA1-4F46-867A-1B69EBECECBCQ43198087-43ECB673-7371-4DE6-8A8A-4D388C5EE86BQ45230734-BF169D2D-8194-4666-9333-1B401671DC89Q51532100-11215CDC-84CB-4CD7-9FC8-768367F7B409Q89663309-3026A72C-159F-44A6-8C62-1978D5313D3EQ90528991-CA4D1A4D-DAC0-47C0-9656-C6A03E8547C5Q90659981-7D0B4ED6-1858-44B9-8F0F-B76794D81E72Q90659989-F4B53614-B95E-482C-9A1E-40F1E30AD083Q91452763-7105E577-3F72-4A0F-ABB4-114ECD7E65AEQ91528195-9E1786AB-C714-472E-B77A-E7866677EBDFQ91838895-1F71C1D5-C0E7-4092-BD65-D114047E6A85Q93109970-D1F1C36F-D4F3-4501-8A84-646095EA91ECQ95266841-D3D49B84-2191-4560-8DC8-DBE5D719D7CF
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Bob T Li
@es
Bob T. Li
@en
Bob T. Li
@sl
type
label
Bob T Li
@es
Bob T. Li
@en
Bob T. Li
@sl
prefLabel
Bob T Li
@es
Bob T. Li
@en
Bob T. Li
@sl
P106
P1153
56953690000
P21
P31
P496
0000-0001-6661-8733
P569
2000-01-01T00:00:00Z